Previous Statements by MYL
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Mylan's CEO Discusses Q2 2011 Results - Earnings Call Transcript
The company could be gearing up for multiple challenges on the D.C. front, analysts say.
With a 100-plus-year history, generous dividend, and diversified portfolio, could this Big Pharma player be resistant to Trump's drug price twitterstorm?